{
  "trial_id": "NCT01593696",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Patient must have a cluster of differentiation 19 (CD19)-expressing B cell ALL or lymphoma and must have relapsed or refractory disease after at least one standard chemotherapy and one salvage regimen.",
      "label": "met"
    },
    {
      "criterion": "CD19 expression must be detected on greater than 15% of the malignant cells by immunohistochemistry or greater than 30% by flow cytometry in a Clinical Laboratory Improvement Amendments (CLIA) approved test in the Laboratory of Pathology, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), or from the referring institution or reference laboratory.",
      "label": "met"
    },
    {
      "criterion": "Patients must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis.",
      "label": "met"
    },
    {
      "criterion": "Greater than or equal to 1 year of age (and at least 15 kg) and less than or equal to 30 years of age.",
      "label": "met"
    },
    {
      "criterion": "Adequate absolute CD3 count estimated to be required to obtain target cell dose based on discussion with Department of Transfusion Medicine (DTM) apheresis and Cell Processing Section, DTM.",
      "label": "unknown"
    },
    {
      "criterion": "Subjects with the following central nervous system (CNS) status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia, such as cranial nerve palsy:",
      "label": "met"
    },
    {
      "criterion": "Ability to give informed consent. For subjects <18 years old their legal guardian must give informed consent.",
      "label": "unknown"
    },
    {
      "criterion": "Clinical performance status: Patients > 10 years of age: Karnofsky greater than or equal to 50%; Patients less than or equal to 10 years of age: Lansky scale greater than or equal to 50%.",
      "label": "met"
    },
    {
      "criterion": "Patients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Recurrent or refractory ALL limited to isolated testicular disease.",
      "label": "not_met"
    },
    {
      "criterion": "Hepatic function: Inadequate liver function defined as total bilirubin > 2x upper limit of normal (ULN) (except in the case of subjects with documented Gilbert's disease > 3x ULN) or transaminase (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 20x ULN based on age and laboratory specific normal ranges;",
      "label": "unknown"
    },
    {
      "criterion": "Renal function: Greater than age-adjusted normal serum creatinine (see below) and a creatinine clearance < 60 mL/min/1.73 m^2.",
      "label": "not_met"
    }
  ],
  "notes": "Patient has Burkitt's lymphoma with pericardial effusion, and has undergone pericardiocentesis and lumbar puncture/bone marrow biopsy. They have a large pericardial mass on cardiac MRI.",
  "_meta": {
    "topic_id": "4",
    "trial_id": "NCT01593696",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}